Genenta Science Plans to Acquire Majority Stake in ATC
Genenta Science intends to target majority ownership in companies with established operating profitability, typically generating up to approximately EUR 5M in EBITDA. In this context, Genenta plans to adopt the new corporate name of Saentra Forge with a new Nasdaq ticker symbol of (SAEN). Saentra Forge intends to pursue a strategy by acquiring targets at private-market valuations and integrating these companies under Saentra Forge. Through this integration, the company will seek to enhance these businesses through operational upgrades, institutional-grade governance, and improved financial visibility. Execution has commenced with ATC, a defense-sector company. Genenta has entered into a binding agreement according to which it will provide funding for ATC through a series of reserved capital increases, via a performance-based and staged acquisition to support operations with the ultimate goal of owning a controlling position in ATC upon the achievement of defined performance milestones. The transaction has received the required clearance under the Golden Power regulatory framework. ATC holds UAMA and SeRNI export-control licenses, NATO qualifications, and authorization from the Italian Ministry of Defense, and its platforms are used by special-forces units and include combat-proven systems. Genenta expects to fund a total of EUR 5.1M in several performance-driven tranches. ATC is projecting revenues of approximately EUR 4M in 2026, increasing to around EUR 9M by 2027. The company operates with a solid net cash position and no outstanding bank debt, reflecting a disciplined management structure. On the profitability side, ATC forecasts EBITDA of more than EUR 2M in 2026, with management expecting EBITDA to approximately double in 2027. In addition, ATC anticipates closing 2026 with a cash balance exceeding EUR 2M, and expects to further strengthen its liquidity position by ending 2027 with cash exceeding EUR 5M. At the core of the company's strategic configuration is the Praexidia Foundation, which has become a shareholder. The Praexidia Foundation is a private law foundation bringing together figures from Italian government institutions, the defense industry, and the armed forces. The company, the foundation, and Pierluigi Paracchi, founder and CEO, have entered into a shareholders' agreement that provides for consultation rights on corporate transactions and a renewable five-year lock-up. The company expects its cash, cash equivalents, and marketable securities at December 31, 2025, to be approximately $33M, compared to $17.7M at June 30, 2025. The increase is primarily due to the company's registered direct offering with certain institutional investors.
Trade with 70% Backtested Accuracy
Analyst Views on GNTA

No data
About GNTA
About the author

- Strategic Acquisition: Genenta Science S.p.A. announced the acquisition of Italian Sòphia High Tech, planning to invest a total of €6 million through two reserved capital increases to achieve a controlling stake, thereby enhancing its market position in biotechnology and defense sectors.
- Performance-Driven Investment: The transaction will be executed in two phases, with the second phase contingent on Sòphia's performance milestones, ensuring effective use of funds to significantly scale production capacity and accelerate technological differentiation.
- Industry Leadership: Since its founding in 2013, Sòphia High Tech has completed over 530 advanced projects, serving top aerospace and defense organizations including the European Space Agency, demonstrating strong profitability and ongoing EBITDA growth potential.
- Technological Innovation and Market Expansion: The acquisition will drive investments in Sòphia's advanced manufacturing technologies, particularly in metal 3D printing and precision machining, further solidifying its leadership in Italy's deep-tech sector to meet growing international demand.

- Company Renaming: Genenta Science S.p.A. is transforming into Saentra Forge, focusing on strategic industrial consolidation in biotech, defense, aerospace, and Italian national security technologies, which is expected to enhance its market competitiveness and industry influence.
- CEO Appointment: CEO Pierluigi Paracchi has been appointed to the Board of Guarantors of the Italian Academy for Advanced Studies, which not only elevates his personal prestige but also strengthens the company's ties with academia in Italy and the U.S., promoting cultural and research exchanges.
- Board Composition: The Board of Guarantors of the Italian Academy consists of twelve members, with six appointed by the Italian government and six by Columbia University, aimed at supporting the Academy's academic and cultural excellence and further solidifying academic ties between Italy and the U.S.
- Strategic Goals: Saentra Forge will focus on acquiring privately held companies in sectors related to Italian national security, including cybersecurity and biosecurity, and is expected to drive long-term growth by integrating resources and technologies in these critical areas.
- Strategic Shift: Genenta Science SPA announced a pivot from biotech to defense and national security, with an extraordinary shareholders meeting scheduled for March 26, marking a significant decision in response to changing market dynamics.
- Acquisition Targets: The company aims to acquire profitable private Italian businesses generating around €5 million in annual EBITDA and has begun scouting for targets, having struck a deal to acquire ATC, a tactical rifles and special-forces weapon systems maker, contingent on meeting specific performance milestones.
- Financial Projections: ATC projects €2.0 million in EBITDA for 2026, expecting to double this in 2027, which will provide robust financial support for Genenta's new business model and enhance its market position.
- Ongoing Biotech Investment: Despite the shift to defense, Genenta plans to continue its biotech programs through partnerships, demonstrating the company's flexibility and foresight in diversifying its business strategy.
- New Board Appointment: Genenta Science has appointed Paolo Salvato to the Board of Directors of ATC, marking the company's initial entry into defense technology manufacturing, which is expected to enhance its strategic position in the defense sector.
- Acquisition Opportunity Evaluation: The company is evaluating majority-control acquisition opportunities in regulated national-security sectors, aiming to build a next-generation strategic industrial consolidator to support technology and scale-up initiatives.
- Biotech Progress: The company announced that its manuscript on clinical findings from the Glioblastoma Multiforme trial has been accepted for publication by Nature Medicine, which is expected to provide significant validation of its scientific and clinical efforts, thereby enhancing market credibility.
- Capital Market Potential: As a publicly listed company, Genenta Science plans to access capital through its Nasdaq listing to support its strategy of acquiring profitable industrial businesses, enhancing financial flexibility and driving long-term value creation.
- Strategic Shift: Genenta Science announced its rebranding to Saentra Forge S.p.A. and plans to acquire privately held businesses with approximately €5 million in EBITDA, marking a strategic pivot towards the defense sector.
- Funding Commitment: The company has entered into an agreement to provide €5.1 million in funding to ATC, which is projected to achieve around €4 million in revenue by 2026 and double its EBITDA by 2027, highlighting the growth potential of this new direction.
- Clinical Milestones: Genenta has reached key clinical milestones aimed at establishing partnerships with major pharmaceutical and biotech firms to accelerate development, improve market access, and enhance strategic value.
- Financial Outlook: Despite a 68.29% decline in stock over the past year, shares are currently trading 87.5% above the 20-day simple moving average, indicating short-term strength, with expectations of cash and equivalents reaching approximately $33 million by the end of 2025.
- Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
- Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
- Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
- Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.








